Ms. Jenna McNeil reports

APPILI THERAPEUTICS ANNOUNCES SECOND AMENDMENT TO ARRANGEMENT AGREEMENT

Appili Therapeutics Inc. has entered into a second amending agreement among the company, Aditxt Inc. and Adivir Inc. to amend the previously announced arrangement agreement dated April 1, 2024, among the parties (as amended on July 1, 2024), pursuant to which Aditxt, through its wholly owned subsidiary, Adivir, will acquire all of the issued and outstanding Class A common shares of the company by way of a court-approved plan of arrangement under the Canada Business Corporations Act. For further information on the transaction, please see the company's news releases dated April 2, 2024, and July 2, 2024, which are available on the company's profile on SEDAR+.

Under the amending agreement: (a) the outside date (as defined in the arrangement agreement) was changed from Aug. 30, 2024, to Sept. 30, 2024; (b) the deadline to convene the company's special shareholders meeting was changed from Aug. 30, 2024, to Sept. 30, 2024; and (c) the deadline for Aditxt to complete the financing (as defined in the arrangement agreement) was changed from Aug. 30, 2024, to Sept. 15, 2024, or such later date as the parties may agree in writing.

A copy of the amending agreement will be available on the company's profile on SEDAR+.

About Appili Therapeutics Inc.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio driven and people focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The company is currently advancing a diverse range of anti-infectives, including a U.S. Food and Drug Administration-approved (FDA) ready-made suspension of metronidazole for the treatment of anti-microbial infections, a vaccine candidate to eliminate a serious biological weapon threat and a topical anti-parasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicentre of the global fight against infection.

We seek Safe Harbor.